Experimental drug tested as last hope for rare, Tough-to-Treat cancers
NCT ID NCT03165721
Summary
This study tested whether a drug called SGI-110 could shrink or slow the growth of certain rare cancers, including specific types of stomach, adrenal, and kidney tumors. It was for patients aged 12 and older whose cancers had not responded to standard treatments. Participants received daily injections of the drug for 5 days, repeated in monthly cycles, while doctors monitored their tumors and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.